Activities
During the 2020-2025 cycle, the CND faculty published 495 manuscripts and are indexed in PubMed: https://www.ncbi.nlm.nih.gov/sites/myncbi/r. lee.mosley.1/collections/66368483/public/
During the 2020-2025 cycle, the CND provides scholastic leadership with editorships for two journals
- Journal of Neuroimmune Pharmacology, Howard E. Gendelman, Editor-in-Chief (March 2006 – December 2021)
- Neuroimmune Pharmacology and Therapeutics, Howard E. Gendelman, Editor-in-Chief (initiated May 2022
The CND faculty has written and/or edited 4 textbooks in current use:
- Neuroimmune Pharmacology and Therapeutics, 3rd ed, Howard E. Gendelman and Tsuneya Ikeu, eds
- The Neurology of AIDS, 3rd ed, Howard E. Gendelman, Igor Grant, Ian Paul Everall, Howard S. Fox, Harris A. Gelbard, Stuart A. Lipton, and Susan Swindells, eds.
- Humanized Mice for HIV Research, Larisa Y. Poluektova, J. Victor Garcia, Yoshio Koyanagi, Markus G. Manz, and Andrew M. Tager, eds
- Current Laboratory Methods in Neuroscience, Huangui Xiong and Howard E. Gendelman, eds
2020-2025 Patents Issued
|
Patent Title |
Patent # |
Issued Date |
CND Faculty |
|
Compositions and Methods for Delivery of Therapeutics |
11,117,904 |
9/14/2021 |
Benson J. Edagwa, Howard E. Gendelman |
|
Antiviral Prodrugs and Nanoformulations Thereof |
11,154,557 |
10/26/2021 |
Howard E. Gendelman, Benson Edagwa |
|
Antiviral Prodrugs and Nanoformulations Thereof |
11,166,957 |
11/9/2021 |
Howard E.. Gendelman, Benson Edagwa |
|
Methods for Diagnosing and Treating Parkinson's Disease Via Measurement of Effector Memory T-Cells |
11,209,426 |
12/28/2021 |
Howard Gendelman, R. Lee Mosley |
|
Compositions and Methods for the Delivery of Therapeutics |
11,311,545 |
4/26/2022 |
Howard E. Gendelman, Benson Edagwa |
|
Antiviral Prodrugs and Nanoformulations Thereof |
11,311,547 |
4/26/2022 |
Howard Gendelman, Benson Edagwa |
|
Non-Human Animal Having Human IL-34 Gene and Use Thereof |
11,419,317 |
8/23/2022 |
Santhi Gorantla, Larisa Poluektova |
|
Antiviral Prodrugs and Formulations Thereof |
11,458,136 |
10/4/2022 |
Howard E. Gendelman, Benson Edagwa |
|
Biomarkers for Monitoring Immune Transformation |
11,806,385 |
11/7/2023 |
Howard E. Gendelman, R. Lee Mosley |
|
Antiviral Prodrugs and Formulations Thereof |
11,839,623 |
12/12/2023 |
Howard E. Gendelman, Benson Edagwa |
|
Methods and Compositions for Inhibiting Diseases of the Central Nervous System |
12,156,912 |
12/3/2024 |
Howard E. Gendelman, R. Lee Mosley |
|
Antiviral Prodrugs and Nanoformulations Thereof |
12,168,013 |
12/17/2024 |
Howard E. Gendelman, Benson Edagwa |
|
Antiviral Prodrugs and Nanoformulations Thereof |
12,257,306 |
3/25/2025 |
Howard E. Gendelman, Benson Edagwa |
2020-2025 Patent Applications Filed
|
Invention Title |
Invention # |
Submission Date |
Inventors |
|
Gene Therapy for HIV-1 Using Tat-Excising CRISPR Cas9 |
20033 |
3/3/2020 |
Howard Gendelman, Jonathan Herskovitz, Mahmudul Hasan |
|
Process of the Generation of Recombinant Kyasanur Forest Disease Virus-like Particles for Candidate Vaccine Use Against Kyasanur Forest Disease |
20062 |
3/25/2020 |
Siddappa Byrareddy |
|
Modular Vaccine Assembled within a Linear DNA Scaffold |
20065 |
4/1/2020 |
Yuri Lyubchenko |
|
SARS-CoV-2 Antigen Design, Production and Testing |
20085 |
5/14/2020 |
Siddappa Byrareddy, Kenneth Bayles, Gloria Borgstahl, Chittibabu Guda, St Patrick Reid |
|
Niclosamide and Prodrugs and Formulations Thereof |
20089 |
7/1/2020 |
Benson Edagwa, Howard Gendelman, St Patrick Reid |
|
Exploiting CRISPR-Cas13 to Develop a Single Cell-Based CNS HIV Reservoir Quantification Assay |
21018 |
10/1/2020 |
Siddappa Byrareddy, Arpan Acharya |
|
Discovery of Coronavirus Entry Inhibitors Including SARS-CoV-2 |
21028 |
10/21/2020 |
Siddappa Byrareddy, Arpan Acharya |
|
Novel Long Acting Slow Effective Release Prodrug Salt Nanocrystals of Buprenorphine, Naltrexone and Naloxone |
21030 |
10/20/2020 |
Benson Edagwa, Howard Gendelman |
|
Development of Lipid Multimodal Mesoporous Silica and Lipid Nanomaterials as CRISPR/Cas9 Plasmid Delivery for HIV-1 Genome Excision |
21045 |
1/20/2021 |
Howard Gendelman, Jonathan Herskovitz, Mahmudul Hasan, Bhavesh Kevadiya, Milankumar Patel |
|
Next Generation Alzheimer’s Disease Mouse Models |
21047 |
1/20/2021 |
Howard Gendelman, Channabasavaiah Gurumurthy, Jatinkumar Machhi, Lee Mosley, Rolen Quadros, Santhi Gorantla, Yaman Lu |
|
Antiviral Prodrugs and Formulations Thereof |
21055 |
2/17/2021 |
Benson Edagwa, Howard Gendelman |
|
Development of a Layer-by-Layer Microparticle for SARS-CoV-2 Vaccine |
21069 |
3/9/2021 |
Howard Gendelman, Bhavesh Kevadiya, Farah Shahjin, Milankumar Patel |
|
Development of New BRD4 and PI3K Inhibitors Small Molecules for Cancer Therapy |
21070 |
3/16/2021 |
Ram Mahato, Yuxiang Dong, Virender Kumar, Bharti Sethi |
|
Biomarkers for Parkinson’s Disease |
21080 |
4/7/2021 |
Howard Gendelman, Lee Mosley, Mai Mostafa, Katehrine Olson |
|
AB-Targeting T Cells for Alzheimer’s Disease |
21084 |
4/16/2021 |
Howard Gendelman, Jatinkumar Machhi, Lee Mosley, Pravin Yeapuri |
|
Synergy of Virus and Host Small Molecules to Target SARS-CoV-2/any Viruses Inhibition Simultaneously |
21088 |
5/1/2021 |
Siddappa Byrareddy, Arpan Acharya |
|
Induction and Expansion of Tregs with GM-CSF and IL-2 |
22008 |
8/11/2021 |
Howard Gendelman, Milica Markovic, Lee Mosley |
|
Proteomic Biomarkers for Parkinson’s Disease |
22010 |
8/25/2021 |
Howard Gendelman, Lee Mosley, Mai Mostafa, Katherine Olson, Jatinkumar Machhi |
|
Functional RNA based Therapeutics Against SARS-CoV-2 Infection |
22015 |
10/4/2021 |
Siddappa Byrareddy |
|
Investigation of the Effects of Different Pore Forming Agents on Polymer-based Microparticles |
22017 |
10/20/2021 |
Howard Gendelman, Bhavesh Kevadiya, Farah Shahjin, Milankumar Patel |
|
Dual Modal Bioimaging Nanoparticle – CulnEuS2 |
22020 |
11/3/2021 |
Howard Gendelman, Bhavesh Kevadiya, Farah Shahjin, Milankumar Patel, Jatinkumar Machhi, Jacob Cohen |
|
Human Interleukin 34 Knock In NSG Mice for Human Microglial Development |
22023 |
11/10/2021 |
Santhi Gorantla |
|
Antiviral Prodrugs and Uses Thereof |
22048 |
2/2/2022 |
Benson Edagwa, Howard Gendelman |
|
Phosphonate Prodrugs and Use Thereof |
22049 |
2/2/2022 |
Benson Edagwa, Howard Gendelman |
|
New Immunodeficient Mouse Strain for Human Immune System Development |
22059 |
3/23/2022 |
Santhi Gorantla |
|
Optimization of Process Parameters for the Microfluidic Production Technique of Lipid Nanoparticles |
22066 |
4/27/2022 |
Howard Gendelman, Bhavesh Kevadiya, Farah Shahjin, Milankumar Patel, Farhana Islam, Jatinkumar Machhi, Mohammad Ullah Nayan |
|
Humanized A-beta Antibody |
22086 |
6/29/2022 |
Howard Gendelman, Lee Mosley, Pravin Yeapuri, Shaurav Bhattarai, Rana Kadry, Jatinkumar Machhi |
|
T Cell Targeted Lipid Nanoparticles for HIV Directed CRISPR Therapy |
23017 |
9/28/2022 |
Howard Gendelman, Mahmudul Hasan, David Oupicky, Lubaba Zaman, Sudipta Panja, Pallavi Deol |
|
Long-Acting GM-CSF for Parkinson’s Disease Treatment |
23020 |
11/16/2022 |
Howard Gendelman, Rana Kadry |
|
Development of Inhba siRNA-PCX Complex to Alleviate the Symptom of Pancreatic Cancer and Pancreatic Cancer-Driven Cachexia |
23027 |
10/19/2022 |
So-Youn Kim, David Oupicky, Seok-Yeong Yu |
|
Optimization of Process Parameters for the Microfluidic Production Technique of LNPs for Anionic homophilic Drug Tracking by Molecular Imaging |
23028 |
10/26/2022 |
Howard Gendelman, Bhavesh Kevadiya, Farhana Islam, Md Ashaduzzaman |
|
Prodrugs of Non-Nucleoside Reverse Transcriptase and Protease Inhibitors |
23037 |
11/30/2022 |
Benson Edagwa |
|
IL-2 Induced Tregs for Neurodegeneration in Parkinson’s Disease |
23055 |
2/22/2023 |
Howard Gendelman, Lee Mosley, Milica Markovic |
|
Compounds, Nanoparticles and Pharmaceutical Compositions for the Treatment of Drug Addiction |
23088 |
6/14/2023 |
Benson Edagwa |
|
HIV-1 Reservoir Targeted LNPs for CRISPR Therapy |
24006 |
8/16/2023 |
Howard Gendelman, Sudipta Panja, Lubaba Zaman, Milankumar Patel |
|
CCR5 Antiviral Drug Nanoprobes Improve HIV-1 Suppression by Drug Delivery to Myeloid Viral Reservoirs |
24007 |
8/16/2023 |
Howard Gendelman, Sudipta Panja, Lubaba Zaman, Milankumar Patel |
|
Posterior Estimation of fMRI Brain Activation for Individual Patients |
24009 |
9/13/2023 |
Michele Aizenberg, David Ellis |
|
Brain Connectivity Mapping Using CEST MRI |
24012 |
10/4/2023 |
Yutong Liu, Dongming Peng |
|
Phosphonate Prodrugs and Use Thereof |
24025 |
10/11/2023 |
Benson Edagwa |
|
Prodrugs of Atovaquone |
24054 |
2/7/2024 |
Benson Edagwa |
|
Novel MDL Series of Phosphodiesterase 4B Inhibitors |
24061 |
3/6/2024 |
Ram Mahato, Yuxiang Dong, Dalton Staller, Donald Ronning |
|
Novel Tool to Protect Cattle from Blood Feeding Insects & Improve Forage Digestibility |
24UNL2024-065 |
4/15/2024 |
Sean Avedissian |
|
Copolymer Prodrugs with Controlled Distribution of Ligands and Methods of Use Thereof |
24080 |
5/1/2024 |
David Oupicky, Sudipta Panja |
|
Structurally Unique Ionizable Lipid for Efficient Delivery of Nucleic Acids |
24081 |
4/24/2024 |
Howard Gendelman, Sudipta Panja |
|
Humanized Alpha-Synuclein Antibody |
24082 |
5/1/2024 |
Howard Gendelman, Lee Mosley, Pravin Yeapuri, Shaurav Bhattarai, Emma Foster, Rana Kadry |
|
Combinatorial Therapy for Alzheimer’s Disease |
25007 |
8/7/2024 |
Howard Gendelman, Lee Mosley, Pravin Yeapuri, Shaurav Bhattarai, Emma Foster, Rana Kadry |
|
LncRNA BACE1-AS is Targeting Small Interfering RNA in Modulating Alcohol-Induced Alzheimer’s-like Pathology and Alcohol Metabolism In Vitro |
25017 |
10/1/2024 |
Susmita Sil, Mohit Kumar |
|
Anti-Inflammatory & Neuroprotective Role of Colostrum Milk EV’s in Parkinson’s Disease |
25021 |
10/30/2024 |
Howard Gendelman, Susmita Sil, Pravin Yeapuri, Sudipta Panja |
|
Disulfide-Based LNPs and Methods of Use Thereof |
25035 |
12/4/2024 |
Howard Gendelman, Sudipta Panja, Soumya Sagar Dey, Bharatbhai Chaudhary, Mohammad Uzair Ali |
|
Neuroprotection of Fucosylated Tregs in a Parkinson’s Disease Model |
25053 |
1/22/2025 |
Howard Gendelman, Pravin Yeapuri |
|
CEST MRI Data Analysis Software Tool |
25055 |
2/5/2025 |
Yutong Liu |
|
Analogs of GLP1 Receptor Agonists and Uses Thereof |
25077 |
3/5/2025 |
Benson Edagwa |
|
HIF-1 targeting therapy in ameliorating Alzheimer’s like pathology in Humanized mice model of HIV infection |
25086 |
3/19/2025 |
Susmita Sil |
|
Optimizing Fucosylation of Tregs to Facilitate Cell Immune Function and Neuroprotection |
25088 |
3/26/2025 |
Howard Gendelman, Guoku Hu, Shefali Srivastava |
CND-Initiated Enterprises
Exavir Therapeutics – A CND faculty-initiated biotech pharmaceutical entity for the development of nanoformulated anti-retroviral therapeutics.. Products planned for clinical trials will be processed through the Nebraska Nanomedicine Production Plant (NNPP), our cGMP facility.
NeuralRegen – A new CND faculty-initiated biotechnology enterprise dedicated to the discovery of therapeutics that can interdict the progression of neurodegenerative pathologies associated with Parkinson’s disease and Alzheimer’s disease. Products in current development include chimeric antigen receptor (CAR) regulatory T cells (Tregs) or CAR-Tregs with specificitie for amyloid beta (Aβ) for Alzheimer’s disease and nitrated α-synuclein (N-α-Syn) for Parkinson’s disease. Products utilized for clinical trials will be manufactured through collaborations with Matt Lunning, DO and the UNMC Biologics Production Facility (BPF).
Current CND Collaborations
Partners Therapeutics – Testing of recombinant human granulocyte/macrophage colony-stimulating factor (rhGM-CSF) (Leukine, sargramostim) in Parkinson’s disease and Alzheimer’s disease
TargaZyme – Collaboration to advance the TZ-101 platform for fucosylation of regulatory T cells (Tregs) to improve extravasation to areas of neuroinflammation and neurodegeneration
Longevity Biotech – Initial pre-clinical evaluation of LBT-3627, a vasoactive intestinal peptide receptor agonist that enhances Treg frequency and function for Parkinson’s disease, multiple \sclerosis (MS), and amyotrophic lateral sclerosis (ALS)
Calibr-Skaggs at Scripps Research - Collaboration on a novel long-acting (antibody fusion) GM-CSF protein designated as PDM-608 that is designed for less frequent dosing in the treatment of neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases
Moderna Therapeutics – Initiated preclinical evaluation of lipid nanoparticle formulated mRNA encoding for mouse serum albumin-GM-CSF fusion protein for Parkinson’s disease
Coya Therapeutics – Licensure of low dose IL-2 technology for development of COYA-301 and COYA-302 to enhance Treg function in neurodegenerative disorders
TG Therapeutics – Collaboration with development of CAR-Tregs for neurodegenerative diseases